SUDDEN CARDIAC DEATH AND METABOLIC SYNDROME

Cover Page

Abstract


In the review epidemiologic data regarding sudden cardiac death in patients with metabolic syndrome are presented. Suspected pathophysiologic mechanisms and approaches to primary prevention of this event are considered.

I S Yavelov

Email: yavelov@yahoo.com

  1. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-3421.
  2. Grundy S.M., Cleeman J.I., Daniels S.R., et al. Diagnosis and Management of the Metabolic Syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-52.
  3. Alberti K.G.M.M., Eckel R.H., Grundy S.M., et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation task force on epidemiology and prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640-5.
  4. Рекомендации экспертов ВНОК по диагностике и лечению метаболического синдрома. Кардиоваскулярная терапия и профилактика 2009; №6, приложение №2.
  5. Чазова И.Е., Мычка В.Б. Метаболический синдром. Москва, Медиа-Медика, 2004, 168 стр.
  6. Bray G.A., Bellanger T. Epidemiology, Trends, and Morbidities of Obesity and the Metabolic Syndrome. Endocrine 2006; 29: 109-117.
  7. Консенсус российских экспертов по проблеме метаболического синдрома: определение, диагностические критерии, первичная профилактика и лечение. Consilium Medicum 2010; 12 (№5): 5-11.
  8. Isomaa B., Almgren P., Tuomi T., et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683-89.
  9. Lakka H.M., Laaksonen D.E., Lakka T.A., et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288: 2709-16.
  10. Hu G., Qiao Q., Tuomilehto J., et al.; DECODE Study Group. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med 2004; 164: 1066-76.
  11. Malik S., Wong N.D., Franklin S.S., et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004; 110: 1245-50.
  12. Ford E.S. The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey II Mortality Study. Atherosclerosis 2004; 173: 309-14.
  13. Hunt K.J., Resendez R.G., Williams K., et al.; San Antonio Heart Study. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation 2004; 110: 1251-57.
  14. Dekker J.M., Girman C., Rhodes T., et al. Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study. Circulation 2005; 112: 666-73.
  15. Ford E.S. Risks for all-cause mortality, cardio-vascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 2005; 28: 1769-78.
  16. ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death - Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). JACC 2006; 48: 1064-1108.
  17. Priori S. G., Aliot E., Blomstrom-Lundqvist C., et al. Task Force on Sudden Cardiac Death of the European Society of Cardiology. Eur Heart J 2001; 22: 1374-1450.
  18. Empana J-P., Duciemetiere P., Balkau B., Jouve X. Contribution of the metabolic syndrome to sudden death risk in asymptomatic men: the Paris Prospective Study I. Eur Heart J 2007; 9: 1149-54.
  19. Resnick H.E., Jones K., Ruotolo G., et al. Insulin Resistance, the Metabolic Syndrome, and Risk of Incident Cardiovascular Disease in Nondiabetic American Indians. The Strong Heart Study. Diabetes Care 2003; 26: 861-67.
  20. Mozaffarian D., Kamineni A., Prineas R.J., Siscovick D.S. Metabolic syndrome and mortality in older adults: the Cardiovascular Health Study. Arch Intern Med 2008; 168: 969-78.
  21. Rachas A., Raffaitin C., Barberger-Gateau P., et al. Clinical usefulness of the metabolic syndrome for the risk of coronary heart disease does not exceed the sum of its individual components in older men and women. The Three-City (3C) Study. Heart 2012; 98: 650-5.
  22. Gale E.A.M. The myth of the metabolic syndrome. Diabetologia 2005; 48: 1679-83.
  23. Kahn R., Buse J., Ferrannini E., Stern M. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005; 28: 2289-2304.
  24. Шурыгина В.Д., Шубик Ю.В. Нарушения ритма сердца при метаболическом синдроме. Вестник аритмологии 2008; №53: 56-63.
  25. Goldberger J.J., Cain M.E., Hohnloser S.H., et al. American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society Scientific Statement on Noninvasive Risk Stratification Techniques for Identifying Patients at Risk for Sudden Cardiac Death. A Scientific Statement From the American Heart Association Council on Clinical Cardiology Committee on Electrocardiography and Arrhythmias and Council on Epidemiology and Prevention. JACC 2008; 52; 1179-99.
  26. Soydinc S., Davutoglu V., Akcay M. Uncomplicated metabolic syndrome is associated with prolonged electrocardiographic QTc interval and QTc dispersion. Ann Noninvasive Electrocardiol 2006; 11: 313-17.
  27. Paksoy F., Ulaş T., Bes C., et al. Corrected Qt interval in patients with metabolic syndrome. Dicle Med J 2011; 38: 274-77.
  28. Li W., Bai Y., Sun K., et al. Patients with Metabolic Syndrome Have Prolonged Corrected QT Interval (QTc). Clin Cardiol 2009; 32: E93-E99.
  29. Сапожникова И.Е., Тарловская Е.И., Тарловский А.К., Соболев А.А. Дисперсия интервалов Q-T И J-T у пациентов с артериальной гипертензией в сочетании с метаболическими нарушениями в рамках инсулинорезистентного синдрома ОМА. Вестник аритмологии 2001; №24: 22-26.
  30. Рябыкина Г.В., Шишова Т.А., Лаптев Д.Н., и соавт. Динамика артериального давления, вариабельности ритма сердца и QTс у больных с метаболическим синдромом при лечении селективным бета-блокатором и бигуанидами. Системные гипертензии 2009; №3: 38-56.
  31. Lown B., Verrier R.L. Neural activity and ventricular fibrillation. N Engl J Med 1976; 294: 1165-70.
  32. Schwartz P.J. The role of the autonomic nervous system in sudden coronary death. Ann Ny Acad Sci 1982; 382; 162-180.
  33. Verrier R.L., Antzelevitch C. Autonomic aspects of arrhythmogenesis: the enduring and the new. Curr Opin Cardiol 2004; 19: 2-11.
  34. Явелов И. С. Вариабельность ритма сердца при сердечно-сосудистых заболеваниях: взгляд клинициста. Сердце 2006; №1: 18-23.
  35. Park S.K., Schwartz J., Weisskopf M. et al. Low-Level Lead Exposure, Metabolic Syndrome, and Heart Rate Variability: The VA Normative Aging Study. Environ Health Perspect 2006; 114: 1718-24.
  36. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Heart Rate Variability. Standards of Measurements, Physiological Interpretation, and Clinical Use. Circulation 1996; 93: 1043-65.
  37. Koskinen T., Kähönen M., Jula A., et al. Metabolic syndrome and short-term heart rate variability in young adults. The cardiovascular risk in young Finns study. Diabet Med 2009; 26: 354-61.
  38. Min K.B., Min J.Y., Paek D., Cho S.I. The impact of the components of metabolic syndrome on heart rate variability: using the NCEP-ATP III and IDF definitions. Pacing Clin Electrophysiol. 2008; 31: 584-91.
  39. Liao D., Sloan R.P., Cascio W.E., et al. Multiple Metabolic Syndrome Is Associated With Lower Heart Rate Variability: The Atherosclerosis Risk in Communities Study. Diabetes Care 1998; 21: 2116-22.
  40. Невзоров В.А., Абрамов Е.А., Власенко А.Н. Особенности липидного спектра, вариабельности артериального давления и сердечного ритма у больных с клиническими проявлениями метаболического синдрома. Вестник аритмологии 2004; №36: 27-30.
  41. Аничков Д.А., Шостак Н.А., Котлярова Л.А., Иванов Д.С. Дисфункция вегетативной нервной системы у больных метаболическим синдромом: исследование вариабельности сердечного ритма. Кардиоваскул. тер. и профилактика 2005; 4 (4): 85-90.
  42. Кратнов А.Е., Климачева О.В., Третьяков С.В. Влияние факторов метаболического синдрома на изменение вариабельности ритма сердца. Современные технологии в медицине 2011; №3: 102-105.
  43. Хурс Е.М., Андреев П. В., Поддубная А. В., и соавт. Вегетативный дисбаланс в патогенезе метаболического синдрома. Клиническая медицина 2010; 88(6): 39-42.
  44. Минаков Э.В., Кудаева Л.А. Изучение особенностей формирования кардиальной нейропатии улиц с метаболическим синдромом и нарушением углеводного обмена (по данным анализа вариабельности сердечного ритма). Саратовский научно-медицинский журнал 2010; 6 (3): 582-85.
  45. Haider A.W., Larson M.G., Benjamin E.J., Levy D. Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. JACC 1998; 32: 1454-59.
  46. Ferrara L.A., Cardoni O., Mancini M., Zanchetti A. Metabolic syndrome and left ventricular hypertrophy in a general population. Results from the Gubbio Study. J Hum Hypertens 2007; 21: 795-801.
  47. Ferrara A.L., Vaccaro O., Cardoni O., et al. Is there a relationship between left ventricular mass and plasma glucose and lipids independent of body mass index? Results of the Gubbio Study. Nutr Metab Cardiovasc Dis 2003; 13: 126-32.
  48. Guerra F., Mancinelli L., Angelini L., et al. The Association of Left Ventricular Hypertrophy with Metabolic Syndrome is Dependent on Body Mass Index in Hypertensive Overweight or Obese Patients. PLoS One 2011; 6(1): e16630.
  49. Alpert M.A. Obesity cardiomyopathy: patho-physiology and evolution of the clinical syndrome. Am J Med Sci 2001; 321: 225-236.
  50. Wong C., Marwick T.H. Obesity cardiomyopathy: pathogenesis and pathophysiology. Nat Clin Pract Cardiovasc Med 2007; 4: 436-43.
  51. Graham I., Atar D., Borch-Johnsen K., et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Pehab 2007; 14 (suppl. 2): S1-S113.
  52. Reiner Z., Catapano A.L., De Backer G., et al. ESC/EAS Guidelines for the management of dyslipidaemias. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011; 32: 1769-1818.
  53. Smith S.C., Benjamin E.J., Bonow R.O., et al. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update. A Guideline From the American Heart Association and American College of Cardiology Foundation. Circulation 2011; 124: 2458-73.
  54. Priori S.G., Aliot E., Blomstrom-Lundqvist C., et al. Update of the guidelines on sudden cardiac death of the European Society of Cardiology. Eur Heart J 2003; 24: 13-15.
  55. Wijns W., Kolh P., Danchin N., et al. Guidelines on myocardial revascularization. The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association for Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2010; 31: 2501-2555.
  56. Higham P.D., Adams P.C., Murray A., Campbell R.W. Plasma potassium, serum magnesium and ventricular fibrillation: a prospective study. Q J Med 1993; 86: 609-17.
  57. Marques J.L., George E., Peacey S.R., et al. Altered ventricular repolarization during hypoglycaemia in patients with diabetes. Diabet Med 1997; 14: 648-54.
  58. Heller S.R. Abnormalities of the electrocardiogram during hypoglycaemia: the cause of the dead in bed syndrome? Int J Clin Pract Suppl 2002; 129: 27-32.
  59. Vgontzas A.N., Bixler E.O., Chrousos G.P. Sleep apnea is a manifestation of the metabolic syndrome. Sleep Med Rev 2005; 9:211-24.
  60. Sharma S.K., Agrawal S., Damodaran D., et al. CPAP for the Metabolic Syndrome in Patients with Obstructive Sleep Apnea. N Engl J Med 2011; 365: 2277-86.
  61. Lattimore J.L., Celermajer D.S., Wilcox I. Obstructive sleep apnea and cardiovascular disease. JACC 2003; 41: 1429-37.
  62. Somers V.K., White D.P., Amin R., et al. Sleep Apnea and Cardiovascular Disease An American Heart Association/American College of Cardiology Foundation Scientific Statement From the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council on Cardiovascular Nursing. JACC 2008; 52; 686-717.

Views

Abstract - 114

PDF (Russian) - 151

PlumX


Copyright (c) 2014 Yavelov I.S.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.